Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-30
2011-08-30
Sznaidman, Marcos L (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C564S084000
Reexamination Certificate
active
08008283
ABSTRACT:
The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na+—K+-2Cl−(NKCC) cotransporter. In certain embodiments, the Na+—K+-2Cl−co-transporter is NKCC1.
REFERENCES:
patent: 3058882 (1962-10-01), Sturm et al.
patent: 3634583 (1972-01-01), Feit
patent: 3665002 (1972-05-01), Popelak
patent: 3676454 (1972-07-01), Vida
patent: 3806354 (1974-04-01), Feit
patent: 3806534 (1974-04-01), Feit
patent: 3971819 (1976-07-01), Feit
patent: 3985777 (1976-10-01), Feit
patent: 3991097 (1976-11-01), Bormann et al.
patent: 4005201 (1977-01-01), Yurugi et al.
patent: 4010273 (1977-03-01), Bormann
patent: 4018929 (1977-04-01), Delarge
patent: 4154652 (1979-05-01), Sawamura et al.
patent: 4247550 (1981-01-01), Feit et al.
patent: 4261985 (1981-04-01), Biollaz
patent: 4309348 (1982-01-01), Asselin et al.
patent: 4340737 (1982-07-01), Johnson
patent: 4351833 (1982-09-01), Johnson
patent: 4663348 (1987-05-01), Chafetz et al.
patent: 4895807 (1990-01-01), Cherksey
patent: 4973600 (1990-11-01), Takamura et al.
patent: 5034109 (1991-07-01), Fujibayashi et al.
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5128327 (1992-07-01), Chakravarty et al.
patent: 5162325 (1992-11-01), Chakravarty et al.
patent: 5201318 (1993-04-01), Rava et al.
patent: 5256687 (1993-10-01), Becker et al.
patent: 5318024 (1994-06-01), Kittrell et al.
patent: 5475008 (1995-12-01), Carling et al.
patent: 5486530 (1996-01-01), Boelke et al.
patent: 5498519 (1996-03-01), Rubin et al.
patent: 5571842 (1996-11-01), Kleemann et al.
patent: 5585401 (1996-12-01), Brandt et al.
patent: 5627077 (1997-05-01), Dyllick-Brenzinger et al.
patent: 5654335 (1997-08-01), Schoenwald et al.
patent: 5658786 (1997-08-01), Smith et al.
patent: 5660181 (1997-08-01), Ho et al.
patent: 5753651 (1998-05-01), DePadova
patent: 5763491 (1998-06-01), Brandt et al.
patent: 5834466 (1998-11-01), Ramasamy et al.
patent: 5902732 (1999-05-01), Hochman
patent: 5976825 (1999-11-01), Hochman
patent: 6040331 (2000-03-01), Yamamoto et al.
patent: 6130234 (2000-10-01), Bigge et al.
patent: 6228873 (2001-05-01), Brandt et al.
patent: 6369094 (2002-04-01), Bentley et al.
patent: 6395781 (2002-05-01), Roman et al.
patent: 6420405 (2002-07-01), Inada et al.
patent: 6432986 (2002-08-01), Levin
patent: 6495601 (2002-12-01), Hochman
patent: 6669951 (2003-12-01), Rothbard et al.
patent: 6894030 (2005-05-01), Hartley
patent: 7199139 (2007-04-01), Takaoka et al.
patent: 7282519 (2007-10-01), Garvey et al.
patent: 2002/0082252 (2002-06-01), Hochman
patent: 2002/0147197 (2002-10-01), Newman et al.
patent: 2005/0065086 (2005-03-01), Kirk et al.
patent: 2005/0203169 (2005-09-01), Moskowitz
patent: 2005/0234107 (2005-10-01), Wank
patent: 2005/0267103 (2005-12-01), Hochman
patent: 2006/0035914 (2006-02-01), Hochman
patent: 2006/0089350 (2006-04-01), Hochman et al.
patent: 2006/0111397 (2006-05-01), Moskowitz
patent: 2007/0043034 (2007-02-01), Staley et al.
patent: 2007/0092510 (2007-04-01), De Koninck et al.
patent: 2007/0155729 (2007-07-01), Morgan et al.
patent: 2007/0293463 (2007-12-01), Dittrich et al.
patent: 2517183 (1975-04-01), None
patent: 2207129 (1999-01-01), None
patent: WO 00/37616 (2000-06-01), None
patent: WO 00/37616 (2000-06-01), None
patent: WO 03/013434 (2003-02-01), None
patent: WO 2005/082350 (2005-09-01), None
patent: WO 2006/058008 (2006-06-01), None
patent: WO 2006/110187 (2006-10-01), None
patent: WO 2006/110187 (2006-10-01), None
patent: WO 2007/042504 (2007-04-01), None
patent: WO 2008/052190 (2008-05-01), None
Dorwald F. A. (Side reactions in organic synthesis, 2005, Wiley, VCH, Weinheim, p. IX of Preface).
Bundgaard, Hans et al., “Photodegradation and Hydrolysis of Furosemide and Furosemide Esters in Azueous Solutions,”International Journal of Pharmaceutics, vol. 42, pp. 217-224 (1988).
Bundgaard, Hans et al., “Glycolamide Esters as a Novel Biolabile Prodrug Type for Non-Steroidal Anti-Inflammatory Carboxylic Acid Drugs,”International Journal of Pharmaceutics, vol. 43, pp. 101-110 (1988).
Granados-Soto, Vinicio et al., “Peripheral and Central Antinociceptive Action of Na+-K+-2Cl−Cotransporter Blockers on Formalin-Induced Nociception in Rats,”Pain, vol. 114, pp. 231-238 (2005).
Hannaert, P. et al., “Rat NKCC2/NKCC1 Cotransporter Selectivity for Loop Diuretic Drugs,”Naunyn-Schmiedeberg's Arch. Pharmacol., vol. 365, pp. 193-199 (2002).
Haglund, Michael M. et al., “Furosemide and Mannitol Suppression of Epileptic Activity in the Human Brain,”J. Neurophysiol., vol. 94, pp. 907-918 (2005).
Mork, Niels et al., “Furosemide Prodrugs: Synthesis, Enzymatic Hydrolysis and Solubility of Various Furosemide Esters,”International Journal of Pharmaceutics, vol. 60, pp. 163-169 (1990).
Prandi, C. et al., “Development of Absorption Furosemide Prodrugs: Synthesis, In Vitro and In Vivo Evaluation,”II Farmaco, vol. 42, No. 2, pp. 249-263 (1992).
Prandi, Carolina et al., “Bioavailability Study of Furosemide Prodrugs in Rats,”II Farmaco, vol. 47, No. 9, pp. 1225-1230 (1992).
“Burinex® K,” intekom.com, Malahyde Information Systems (1996-2004).
“Strategies for Optimizing Migraine Management,”Proceedings From A CME Teleconference Series, 1-26 (especially p. 8, para. 5) (2001).
“The Migraineur's Guide to Migraine,” http://www.headachecare.com (2000).
Ahmad et al., “Controlled Trial of Furosemide As An Antiepileptic Drug In Focal Epilepsy”Br. J. Clin Pharmac. 3: 621-625 (1976).
Akerman, S., Goadsby, P. J., “Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura,”Neuroreport16(12): 1383-7 (Abstract) (2005).
Barbaro, N. M. et al., “A Potential Role for Astrocytes in Mediating the Antiepileptic Actions of Furosemide In Vitro,”Neuroscience128: 655-663 (2004).
Batham et al., “Diazepam in Combination with Antiepileptic Drugs—An Experimental Study,”Indian J. Med. Res. 66: 872-875 (1977).
Bazil, Carl W. et al., “Advances in the Medical Treatment of Epilepsy,”Annu. Rev. Med. 49: 135-162 (1998).
Bikson, M. et al., “Inhibition of Nonsynaptic Epileptiform Activity in the Hippocampus,”Society for Neuroscience 24: 1213 (Abstract) (1998).
Carter, C. H., “Status Epilepticus Treated by Intravenous Urea,”Epilepsia 3: 198-200 (1962).
Collins, M. A. et al., “Brian damage due to episodic alcohol exposure in vivo and in vitro: furosemide neuroprotection implicates edema-based mechanism,”FASEB J. 12: 221-230 (1998).
Cragoe, E. J., Jr., et al., “Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids,”J. Med. Chem. 25(5): 567-579 (May 1982).
Diener, H. C. et al., “Emerging Treatments in Headache,”European Neurology 38(3): 167-174 (Abstract) (1997).
Dzhala et al., “NKCC1 Transporter Facilitates Seizures in the Developing Brain,”Nature Medicine11(11): 1205-1213 (2005).
Ebersberger, Andrea et al., “Is There a Correlation Between Spreading Depression, Neurogenic Inflammation, and Nociception That Might Cause Migraine Headache?”Ann. Neurol. 49(1): 7-13 (Jan. 2001).
Ellory, J. C.; Stewart, G. W. “The Human Erythrocyte Cl-Dependent Na-K Cotransport System as a Possible Model for Studying the Action of Loop Diuretics,”Br. J. Pharmac. 75(1): 183-188 (1982).
Espinosa, X. Jimenez “Efecto Anticonvulsivante Del Seguril”Tomo 61(361): 280-282 (1969).
Ettmayer et al., “Lessons Learned from Marketed and Investigational Prodrugs”J. Med. Chem. 47(10): 2394-2404 (2004).
Feit, P. W., “Aminobenzoic Acid Diuretics. 2. 4-Substituted-3-amino-5-sulfamylbenzoic Acid Derivatives,”Journal of Med. Chem. 14(5): 432-439 (1971).
Feit, P. W. et al., “Purification of Proteins of the
Hochman Daryl W.
Partridge John J.
Hunton & Williams LLP
Neurotherapeutics Pharma, Inc.
Sznaidman Marcos L
LandOfFree
Methods and compositions for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2776780